A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets
Neoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells. With high specificity and immunogenicity, neoantigens are considered as an ideal target for immunotherapy. This study was aimed to investigate the signature of neoantigens in breast cancer. Somatic mu...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.786438/full |
| _version_ | 1818775298314862592 |
|---|---|
| author | Si Zhou Songming Liu Lijian Zhao Hai-Xi Sun |
| author_facet | Si Zhou Songming Liu Lijian Zhao Hai-Xi Sun |
| author_sort | Si Zhou |
| collection | DOAJ |
| description | Neoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells. With high specificity and immunogenicity, neoantigens are considered as an ideal target for immunotherapy. This study was aimed to investigate the signature of neoantigens in breast cancer. Somatic mutations, including SNVs and indels, were obtained from cBioPortal of 5991 breast cancer patients. 738 non-silent somatic variants present in at least 3 patients for neoantigen prediction were selected. PIK3CA (38%), the highly mutated gene in breast cancer, could produce the highest number of neoantigens per gene. Some pan-cancer hotspot mutations, such as PIK3CA E545K (6.93%), could be recognized by at least one HLA molecule. Since there are more SNVs than indels in breast cancer, SNVs are the major source of neoantigens. Patients with hormone receptor-positive or HER2 negative are more competent to produce neoantigens. Age, but not the clinical stage, is a significant contributory factor of neoantigen production. We believe a detailed description of breast cancer neoantigen signatures could contribute to neoantigen-based immunotherapy development. |
| first_indexed | 2024-12-18T10:54:49Z |
| format | Article |
| id | doaj.art-ac605b03f58e454e8d87d78b063ef91f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-18T10:54:49Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ac605b03f58e454e8d87d78b063ef91f2022-12-21T21:10:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.786438786438A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic TargetsSi Zhou0Songming Liu1Lijian Zhao2Hai-Xi Sun3College of Life Sciences, University of Chinese Academy of Sciences, Beijing, ChinaCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing, ChinaCollege of Medical Technology, Hebei Medical University, Shijiazhuang, ChinaCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing, ChinaNeoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells. With high specificity and immunogenicity, neoantigens are considered as an ideal target for immunotherapy. This study was aimed to investigate the signature of neoantigens in breast cancer. Somatic mutations, including SNVs and indels, were obtained from cBioPortal of 5991 breast cancer patients. 738 non-silent somatic variants present in at least 3 patients for neoantigen prediction were selected. PIK3CA (38%), the highly mutated gene in breast cancer, could produce the highest number of neoantigens per gene. Some pan-cancer hotspot mutations, such as PIK3CA E545K (6.93%), could be recognized by at least one HLA molecule. Since there are more SNVs than indels in breast cancer, SNVs are the major source of neoantigens. Patients with hormone receptor-positive or HER2 negative are more competent to produce neoantigens. Age, but not the clinical stage, is a significant contributory factor of neoantigen production. We believe a detailed description of breast cancer neoantigen signatures could contribute to neoantigen-based immunotherapy development.https://www.frontiersin.org/articles/10.3389/fonc.2022.786438/fullbreast cancerneoantigensimmunotherapyPIK3CASNVs |
| spellingShingle | Si Zhou Songming Liu Lijian Zhao Hai-Xi Sun A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets Frontiers in Oncology breast cancer neoantigens immunotherapy PIK3CA SNVs |
| title | A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets |
| title_full | A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets |
| title_fullStr | A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets |
| title_full_unstemmed | A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets |
| title_short | A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets |
| title_sort | comprehensive survey of genomic mutations in breast cancer reveals recurrent neoantigens as potential therapeutic targets |
| topic | breast cancer neoantigens immunotherapy PIK3CA SNVs |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.786438/full |
| work_keys_str_mv | AT sizhou acomprehensivesurveyofgenomicmutationsinbreastcancerrevealsrecurrentneoantigensaspotentialtherapeutictargets AT songmingliu acomprehensivesurveyofgenomicmutationsinbreastcancerrevealsrecurrentneoantigensaspotentialtherapeutictargets AT lijianzhao acomprehensivesurveyofgenomicmutationsinbreastcancerrevealsrecurrentneoantigensaspotentialtherapeutictargets AT haixisun acomprehensivesurveyofgenomicmutationsinbreastcancerrevealsrecurrentneoantigensaspotentialtherapeutictargets AT sizhou comprehensivesurveyofgenomicmutationsinbreastcancerrevealsrecurrentneoantigensaspotentialtherapeutictargets AT songmingliu comprehensivesurveyofgenomicmutationsinbreastcancerrevealsrecurrentneoantigensaspotentialtherapeutictargets AT lijianzhao comprehensivesurveyofgenomicmutationsinbreastcancerrevealsrecurrentneoantigensaspotentialtherapeutictargets AT haixisun comprehensivesurveyofgenomicmutationsinbreastcancerrevealsrecurrentneoantigensaspotentialtherapeutictargets |